Can a lung drug tame the pain of chronic pancreatitis?

NCT ID NCT07755813

Not yet recruiting Disease control Sponsor: Vikas Dudeja Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether pirfenidone, a drug already used for lung scarring, can help people with chronic pancreatitis—a long-term inflammation of the pancreas that causes severe pain. The study will enroll 60 adults with chronic pancreatitis and moderate-to-severe pain. Participants will take either pirfenidone or a placebo for 48 weeks. Researchers will track side effects and whether the drug reduces emergency room visits for pancreatitis-related pain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pirfenidone
What this could lead to: If successful, pirfenidone could become a new treatment to reduce pain and flare-ups in chronic pancreatitis, potentially slowing disease progression.
What could go wrong: This is an early-stage trial with a small number of participants. Pirfenidone may not prove more effective than placebo, and it can cause side effects like nausea, rash, or liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC PANCREATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic pancreatitis pancreatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC PANCREATITIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.